Certainly more studies will need to be done in this area of pediatric asthma. FENO may remain a useful marker for assessing patients at the time of diagnosis and also to help monitor the level of asthma control of individual patients in clinical practice.

REFERENCES


Exhaled Nitric Oxide in Children with Asthma

RESPIRATORY CARE NURSE’S PERSPECTIVE

HELEN PETSKY

Queensland Children’s Medical Research Institute, Queensland University of Technology, Royal Children’s Hospital, Herston, Queensland, Australia. helenpetsky@gmail.com

Asthma is one of the most common chronic diseases in children. Acute exacerbations are not uncommon in children with asthma and many are hospitalized. Not surprisingly, hospitalizations for asthma are very common, accounting for 12-21% of hospitalizations worldwide [1]. Thus prevention of exacerbations, particularly severe ones, is one goal of good asthma management. The second component in asthma management is monitoring of asthma control, by both subjective and objective measures [2-4]. Subjective measures usually involve a series of questions used for clinical assessment, diary cards and quality of life (QoL) questionnaires. Traditional objective methods include peak flow meters, spirometry and degree of airway hyperresponsiveness (AHR). Newer and arguably more sensitive methods include measurement of airway inflammation such as airway cellularity in induced sputum or fractional exhaled nitric oxide (FENO). In asthma, inflammation can be eosinophilic or non-eosinophilic. In patients with eosinophilic inflammation, the use of inhaled corticosteroids (ICS) reduces exacerbations and improves symptoms and asthma control. FENO correlates with other markers of asthma eg. eosinophilia in induced sputum [5] and bronchial reactivity in non-steroid treated subjects [6].

The first study to use FENO as a biomarker was published by Dupont and colleagues [6] in 1998. They measured FENO in steroid treated and untreated adults with mild asthma. These levels correlated with the degree of AHR as measured by the dose of histamine required to produce a 20% decrease in forced expiratory volume in first second (FEV<sub>1</sub>). The authors concluded that FENO levels reflect AHR in patients with mild asthma who were steroid naïve. The adults who were treated with ICS had similar FENO levels as the healthy controls [6].

As asthma in adults is not identical to that in children, data relating FENO and asthma control specific to children is important. There are many studies that have related FENO with various clinical aspects of asthma in children. Byrnes, et al. [7] recruited 39 children as
controls from local school and 31 children with a clinical diagnosis of asthma. The aims of the study were to determine if FENO could be measured in children, and whether the pattern seen in adults with asthma versus adult controls is observed in children with asthma on bronchodilators only, had the highest FENO level. The FENO levels for children with asthma on regular ICS was not statistically different from the control children [7]. As FENO relates to airway eosinophilic inflammation, FENO as a biomarker can be potentially used in children with asthma to monitor the response to (and hence adjust) asthma medications, verify the adherence to ICS, and predict upcoming asthma exacerbations. Based on data above that showed the potential value of using FENO in improving asthma outcomes, the research undertaken by Raj, et al. [8] has provided further evidence that FENO levels increase during an asthma exacerbation but may not provide any clinical significance.

A Cochrane review [9] assessing the efficacy of tailoring asthma interventions based on FENO levels versus clinical symptoms for improving asthma related outcomes has been undertaken. The review includes 6 studies (2 adult studies and 4 involving children or adolescents). These studies differed in definition of asthma exacerbations, FENO cut-off levels used to determine adjustment of medications, type of therapy adjustment and the duration of studies. In the meta-analysis, there was no significant difference between groups for the primary outcome of asthma exacerbations, or for other outcomes (clinical symptoms, FENO level and spirometry). In post-hoc analysis, a significant reduction in mean final daily dose inhaled corticosteroid per adult was found in the group where treatment was based on FENO in comparison to clinical symptoms, (mean difference -450 mcg; 95% CI -677 to -222 mcg budesonide equivalent/day). However, the total amount of inhaled corticosteroid used in one of the adult studies was 11% greater in the FENO arm. In contrast, in the pediatric studies, there was a significant increase in inhaled corticosteroid dose in the FENO strategy arm (mean difference of 140 mcg; 95% CI 129 to 251 mcg budesonide equivalent/day). These results have limited applicability, the most significant issue was that none of the six included studies considered presence or severity of atopy in their algorithm of management although some but not all subjects were atopic. This is important because atopy influences FENO levels regardless of the presence of asthma.

Funding: None; Competing interest: None stated.

REFERENCES